“A Case Report Overwhelming response to TNF-alfa inhibitor Infliximab “innovator” Vs. Adalimumab ‘Bio-similar’ in a previously therapy naive adult” (2022) Indian Journal of Case Reports, 8(3), pp. 58–61. doi:10.32677/ijcr.v8i3.3317.